Adagio Medical to Present at the BofA Securities 2025 Health Care Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

05/07/2025 - 08:30 AM

LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the BofA Securities Health Care Conference on Tuesday, May 13, 2025, at 9:20 a.m. PT at the Encore Hotel in Las Vegas, NV.

Presentation Information
A live and recorded webcast of the presentation will be available at: https://bofa.veracast.com/webcasts/bofa/healthcare2025/id5FQ7Pq.cfm

About Adagio Medical

Adagio Medical is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizing its novel, proprietary, catheter-based Ultra-Low Temperature Cryoablation (ULTC) technology. ULTC is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The Company is currently focused on the treatment of ventricular tachycardia (VT) with its purpose-built vCLAS^TM Cryoablation System, which is CE Marked and is currently under evaluation in the Company’s FULCRUM-VT U.S. IDE Pivotal Study.